Horizon Kinetics Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Horizon Kinetics Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$402K	Sell	645 -30	-4%	-$20.4K	﹤0.01%	236
2026 Q1	$522K	Sell	675 -30	-4%	-$23K	0.01%	221
2025 Q4	$544K	Sell	705 -30	-4%	-$20.4K	0.01%	214
2025 Q3	$413K	Buy	735 +30	+4%	+$17K	0.01%	251
2025 Q2	$370K	Sell	705 -30	-4%	-$16.7K	﹤0.01%	270
2025 Q1	$466K	Hold	735	–	–	0.01%	240
2024 Q4	$524K	Buy	735 +29	+4%	+$24.3K	0.01%	229
2024 Q3	$742K	Sell	706 -30	-4%	-$33.4K	0.01%	208
2024 Q2	$774K	Hold	736	–	–	0.01%	185
2024 Q1	$708K	Buy	736 +1	+0.1%	+$951	0.01%	191
2023 Q4	$646K	Sell	735 -30	-4%	-$24.7K	0.01%	192
2023 Q3	$630K	Hold	765	–	–	0.01%	196
2023 Q2	$550K	Hold	765	–	–	0.01%	212
2023 Q1	$629K	Buy	+765	New	+$577K	0.01%	197

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Horizon Kinetics Asset Management's REGN Position: Q2 2026 in Review

Horizon Kinetics Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 4.4% in Q2 2026, selling an estimated $20.4K and leaving 645 shares worth $402K. The position accounts for ﹤0.01% of the portfolio, ranked #236.

Horizon Kinetics Asset Management first reported a position in REGN in Q1 2023 and has held it in 14 quarters since. The position peaked at $774K in Q2 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Horizon Kinetics Asset Management held 645 shares of Regeneron Pharmaceuticals worth $402K as of Q2 2026.
Horizon Kinetics Asset Management sold 30 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $20.4K.
Regeneron Pharmaceuticals made up ﹤0.01% of Horizon Kinetics Asset Management's portfolio in Q2 2026, its #236 holding.
Horizon Kinetics Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
Horizon Kinetics Asset Management's Regeneron Pharmaceuticals position peaked at $774K in Q2 2024.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Horizon Kinetics Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.